The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.

Among adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamine treatment, remibrutinib improved ...

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...

Dupixent has gained EU approval as the first targeted therapy in more than ten years for chronic spontaneous urticaria, ...

Patients with chronic spontaneous urticaria (CSU) experienced improved quality of life and sleep when symptoms were mitigated ...

(BPT) – If you’ve had hives, you know how challenging they can be. But you may not know that there is more than one type of hives, or urticaria, and that treatments are available. A brief episode of ...

Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (“CSU”) in adults ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Chronic urticaria is an inflammatory skin disorder characterised by recurrent transient wheals and/or angioedema that persist for more than six weeks. Within this spectrum, chronic spontaneous ...

A recent systematic review of 14 studies assessed the prevalence and impact of SxD in patients with CU. CU patients with sexual issues reported more disease activity, poorer quality of life, worse ...

Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years ...